文献
J-GLOBAL ID:202002234453691168
整理番号:20A0206860
中間リスク核型を有する後成的修飾因子遺伝子変異陽性AML患者はCAGレジメンによるデシタビンから利益を得る【JST・京大機械翻訳】
Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen
著者 (9件):
Xu Qingyu
(Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing, China)
,
Li Yan
(Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing, China)
,
Jing Yu
(Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing, China)
,
Lv Na
(Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing, China)
,
Lv Na
(Department of Hematology-Oncology, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, Shenzhen, China)
,
Wang Lili
(Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing, China)
,
Li Yonghui
(Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing, China)
,
Yu Li
(Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing, China)
,
Yu Li
(Department of Hematology-Oncology, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, Shenzhen, China)
資料名:
International Journal of Cancer
(International Journal of Cancer)
巻:
146
号:
5
ページ:
1457-1467
発行年:
2020年
JST資料番号:
A0267B
ISSN:
0020-7136
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)